Levena Biopharma

Levena Biopharma is a privately held company located in San Diego, United States. With a workforce of 100 to 249 employees, Levena Biopharma generates an estimated revenue of $50 million. As a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), Levena Biopharma specializes in the development and manufacturing of Antibody Drug Conjugates (ADCs). Their services cater to pharmaceutical and biotechnology companies seeking to advance ADC programs from discovery to clinical trials and beyond. Levena Biopharma offers a comprehensive suite of ADC-related services, including small and large-scale proof-of-concept conjugation, complete ADC characterization using advanced analytical tools, quality assessment, and in vitro pharmacology for cytotoxicity studies. Levena Biopharma differentiates itself through its proprietary and non-proprietary ADC solutions encompassing linkers, payloads, L-P chemistries, and site-specific conjugation platforms. These platforms, including C-Lock™, K-Lock™, and C-Lock™/K-Lock™ for dual-drug delivery, enable the development of ADCs with precisely defined mechanisms of action, ensuring safety, efficacy, and clinical success. Interested parties can connect with Levena Biopharma through their website at levenabiopharma.com.